ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

10,492Medicare Part D Prescriptions Filled, Including Refills

Rank: 92 out of 761

$419K Total Retail Price of All Prescriptions

Rank: 191 out of 761

506 Patients Receiving at Least One Drug in Part D
82%Patients 65 Years and Older
41% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Oregon
Lower avg

Schedule Two
Controlled Substances

12% of this provider’s 506 patients filled at least one prescription for a schedule two drug, compared to an average of 9%.

Schedule Three
Controlled Substances

12% of this provider’s 506 patients filled at least one prescription for a schedule three drug, compared to an average of 13%.

Risky Drugs to Seniors

2% of this provider’s 8,156 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

20% of this provider’s prescriptions were for brand-name drugs, compared to an average of 23%.

Prescription Price

$40 was the average price of a prescription from this provider, compared to $54 among peers.

Prescriptions per Patient

21 is the average number of prescriptions (including refills) per patient, compared to an average of 17.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Oregon
LISINOPRIL 745 565 1 1
LEVOTHYROXINE SODIUM 535 379 2 3
OMEPRAZOLE 507 430 3 4
HYDROCHLOROTHIAZIDE 423 377 4 11
ATENOLOL 415 371 5 8
SIMVASTATIN 337 282 6 2
FUROSEMIDE 273 249 7 7
AMLODIPINE BESYLATE 272 242 8 6
LOSARTAN POTASSIUM 243 217 9 13
POTASSIUM CHLORIDE 209 181 10 18
ALENDRONATE SODIUM 205 151 11 21
LOVASTATIN 202 184 12 17
ATORVASTATIN CALCIUM 199 157 13 12
GABAPENTIN 197 125 14 15
METFORMIN HCL 184 139 15 10
ZOLPIDEM TARTRATE 165 112 16 22
HYDROCODONE-ACETAMINOPHEN 165 116 S3 16 5
KLOR-CON 10 134 116 18 74
TRAMADOL HCL 127 90 19 34
OXYCODONE HCL 115 68 S2 20 24
FLUOXETINE HCL 110 105 21 31
METOPROLOL TARTRATE 109 105 22 14
DONEPEZIL HCL 108 108 23 33
CITALOPRAM HBR 105 69 24 19
NAPROXEN 92 68 25 105
METOPROLOL SUCCINATE 84 48 26 16
PAROXETINE HCL 83 57 27 47
BUPROPION HCL SR 79 70 28 93
GLIPIZIDE 77 62 29 39
BENICAR 76 65 30 81
TRAZODONE HCL 71 38 31 23
PROAIR HFA 70 47 32 32
OXYCONTIN 69 23 S2 33 114
ALLOPURINOL 67 61 34 28
GLYBURIDE 66 56 R 35 77
PREDNISONE 64 46 36 30
OXYCODONE-ACETAMINOPHEN 62 49 S2 37 49
TRIAMTERENE-HYDROCHLOROTHIAZID 62 54 37 68
LANTUS 59 26 39 41
CARISOPRODOL 58 0 R 40 131
PRAVASTATIN SODIUM 56 34 41 20
AZITHROMYCIN 55 48 42 70
ADVAIR DISKUS 53 36 43 37
CARVEDILOL 51 44 44 26
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on June 4, 2010.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.